Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04699305
Recruitment Status : Recruiting
First Posted : January 7, 2021
Last Update Posted : January 8, 2021
Sponsor:
Information provided by (Responsible Party):
RedDress Ltd.

Brief Summary:
Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.

Condition or disease Intervention/treatment
Cutaneous Wounds Device: ActiGraft

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: An Observational Clinical Registry to Collect Safety and Efficacy Data on Wound Care in Medical Centers
Actual Study Start Date : February 14, 2019
Estimated Primary Completion Date : February 1, 2022
Estimated Study Completion Date : February 28, 2022

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
ActiGraft
Whole blood clot (WBC) gel
Device: ActiGraft
Whole blood clot (WBC) gel




Primary Outcome Measures :
  1. Percentage area reduction (PAR) at 4 weeks [ Time Frame: 4 weeks ]
    Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).

  2. Nature, frequency, and severity of adverse events in the intent to treat population [ Time Frame: 1 year ]
    Nature, frequency, and severity (by CTCAE5) of adverse events


Secondary Outcome Measures :
  1. Percentage area reduction at 8 and 12 weeks [ Time Frame: 12 weeks ]
    Change from baseline at 8 and 12 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).


Other Outcome Measures:
  1. Reduction in pain at 4 weeks [ Time Frame: 4 weeks ]
    Pain reduction at 4 weeks for wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT) for patients reporting any level of wound related pain (>1 on a VAS scale of 0-10 points) at baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Patients with all types of exuding cutaneous wound
Criteria

Inclusion Criteria:

  • Subject is ≥18 years of age
  • Subject has an exuding cutaneous wound
  • Subject agrees to the use of his health data, including photos of his wound in analysis and publications
  • Subject/LAR must be able to read and understand English and/or Spanish

Exclusion Criteria:

  • Subject/LAR is unable to read and understand English or Spanish.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04699305


Contacts
Layout table for location contacts
Contact: Sharon Sirota +972545800765 sharon@reddress.co.il

Locations
Layout table for location information
United States, Nevada
Wound Care Experts Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Naz Wahab, M.D         
Sponsors and Collaborators
RedDress Ltd.
Investigators
Layout table for investigator information
Study Director: Sharon Sirota RedDress Ltd.
Layout table for additonal information
Responsible Party: RedDress Ltd.
ClinicalTrials.gov Identifier: NCT04699305    
Other Study ID Numbers: RD005
First Posted: January 7, 2021    Key Record Dates
Last Update Posted: January 8, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The results will be part of several scientific publications
Supporting Materials: Study Protocol
Time Frame: Upon publication

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by RedDress Ltd.:
DFU, PU, Surgical, Vascular, Trauma
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries